SP-420 is under clinical development by Pharmacosmos and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 38% phase transition success ...

Trilaciclib is under clinical development by Pharmacosmos and currently in Phase III for Triple-Negative Breast Cancer (TNBC).

Both Ferinject and Monofer are high-dose intravenous iron medicines indicated for the treatment of iron deficiency when ... including Pharmacosmos, to reference the information in their own ...

The CMA looked into allegations that Vifor Pharma spread misinformation about the safety of Monofer, an alternative treatment supplied by Pharmacosmos. Iron deficiency anaemia, a condition ...

The CMA looked into allegations that Vifor Pharma spread misinformation about the safety of Monofer, an alternative treatment supplied by Pharmacosmos. Iron deficiency anaemia, a condition ...